Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
56 hedge funds and large institutions have $17.8M invested in Viracta Therapeutics, Inc. Common Stock in 2022 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 11 closing their positions.
983% more call options, than puts
Call options by funds: $65K | Put options by funds: $6K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
5% less funds holding
Funds holding: 59 → 56 (-3)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
66% less capital invested
Capital invested by funds: $52.8M → $17.8M (-$35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$982K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$281K |
| 3 |
Two Sigma Investments
New York
|
+$175K |
| 4 |
Millennium Management
New York
|
+$142K |
| 5 |
Renaissance Technologies
New York
|
+$128K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$627K |
| 2 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$615K |
| 3 |
Goldman Sachs
New York
|
-$502K |
| 4 |
E
Ergoteles
New York
|
-$329K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$127K |
VIRX Hedge Fund Activity: Q4 2022 in Review
56 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q4 2022, worth a combined $17.8M — down 66% from $52.8M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of VIRX and 9 opened new positions — a net loss of 2 holders — while 14 trimmed existing stakes and 13 added.
The largest buyer was Rubric Capital Management (New York), adding an estimated $982K. The largest seller was BlackRock, cutting an estimated $627K.
- 56 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q4 2022, down from 59 in Q3 2022.
- Funds reported $17.8M of Viracta Therapeutics, Inc. Common Stock stock for Q4 2022, down 66% quarter-over-quarter.
- 9 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q4 2022 and 11 closed out, a net change of -2 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q4 2022 was Rubric Capital Management (New York), an estimated $982K added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q4 2022 was BlackRock, an estimated $627K sold.
Based on aggregated 13F filings for Q4 2022.